Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 3/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17535141 | 0.90 | ALDH3A1 (0.39) | HTTALDH3A1POLBNOD1L3MBTL1 | |
| SCHEMBL20536259 | 0.88 | ABL1 (0.42) | HTTALDH3A1POLBNOD1L3MBTL1 | |
| SCHEMBL1749189 | 0.88 | PTGDR2 (0.37) | HTTALDH3A1POLBNOD1L3MBTL1 | |
| SCHEMBL28563225 | 0.84 | MEN1 (0.39) | HTTALDH3A1POLBNOD1L3MBTL1 | |
| SCHEMBL1749021 | 0.84 | PTGDR2 (0.44) | HTTALDH3A1POLBNOD1L3MBTL1 | |
| SCHEMBL5413878 | 0.81 | NOD1 (0.39) | HTTALDH3A1POLBNOD1L3MBTL1 | |
| SCHEMBL16977994 | 0.80 | PTGDR2 (0.40) | HTTALDH3A1L3MBTL1PTGDR2LMNA | |
| SCHEMBL1749156 | 0.78 | PTGDR2 (0.46) | HTTALDH3A1POLBNOD1L3MBTL1 | |
| SCHEMBL1354815 | 0.78 | CDK2 (0.39) | HTTALDH1A1KDM4ENPSR1HSD11B1 | |
| SCHEMBL16051988 | 0.77 | CCNT1 (0.46) | POLBLMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796708-B2 | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2970278-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970264-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9073922-B2 | Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors | ABBVIE, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| WO-2014151444-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
| WO-2014139328-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2569316-B1 | PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2569316-A1 | PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011143459-A1 | PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110281842-A1 | PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | HTT 4362/4885ALDH3A1 2381/4885POLB 156/4885 |
| US-20110281842-A1 | PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | HTT 3562/4885ALDH3A1 2516/4885POLB 629/4885 |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | HTT 4627/4885ALDH3A1 3103/4885POLB 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.